ArticleJournal of molecular graphics & modelling2022
Predicting novel drug candidates against Covid-19 using generative deep neural networks.
Article in Journal of molecular graphics & modelling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrated analysis of RNA-binding proteins in MAFLD: mechanistic insights and diagnostic biomarker potential via alternative splicing.Journal of bioenergetics and biomembranes · 2025Article
- Navigating with chemometrics and machine learning in chemistry.Artificial intelligence review · 2023Article
- A review of SARS-CoV-2 drug repurposing: databases and machine learning models.Frontiers in pharmacology · 2023Review
- Zirconium-Based Metal-Organic Frameworks as Acriflavine Cargos in the Battle against Coronaviruses─A Theoretical and Experimental Approach.ACS applied materials & interfaces · 2022Article
- Machine learning applications for COVID-19 outbreak management.Neural computing & applications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel Coronavirus outbreak has created a massive economic crisis, and many succumb to death, disturbing the lives of mankind all over the world. Currently, there are no viable treatment for this condition, drug development approaches are being pursued with vigor. The major treatment options are to repurpose existing drugs or to find new ones. Traditional methods for drug discovery take a longer time, so there is an urgent need to develop some alternative techniques that reduces search space for drug candidates. Towards this endeavor, we propose a novel drug discovery method that leverages on long short term memory (LSTM) model to generate novel molecules that are adept at binding with novel Coronavirus protease. Our study demonstrates that the proposed method is able to recreate novel molecules that correlate very much with the properties of trained molecules. Further, we fine-tune the model to generate novel drug-like molecules that are active towards a specific target. We consider 3CLPro, the main protease of novel Coronavirus, as a therapeutic target and demonstrated in silico screening to assess target structural binding affinities with docking simulations. We observed that 80% of generated molecules show docking free energy of less than -5.8 kcal/mol. The top generated drug candidate has the highest binding affinity with a docking score of -8.5 kcal/mol, which is very much lower when compared to approved existing commercial drugs including, Remdesivir. The low binding energy indicates that the generated molecules could be explored as potential drug candidates for Covid-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.